Dataset: Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks. 96 samples

Species:

human

Samples:

96

Source:

E-GEOD-48906

Updated:

Dec.12, 2014

Registered:

Jul.11, 2014